Cellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, 11525 Athens, Greece.
Int J Mol Sci. 2020 Oct 26;21(21):7930. doi: 10.3390/ijms21217930.
Allergic asthma is a chronic inflammatory disease of the airways characterized by airway hyperresponsiveness (AHR), chronic airway inflammation, and excessive T helper (Th) type 2 immune responses against harmless airborne allergens. Dendritic cells (DCs) represent the most potent antigen-presenting cells of the immune system that act as a bridge between innate and adaptive immunity. Pertinent to allergic asthma, distinct DC subsets are known to play a central role in initiating and maintaining allergen driven Th2 immune responses in the airways. Nevertheless, seminal studies have demonstrated that DCs can also restrain excessive asthmatic responses and thus contribute to the resolution of allergic airway inflammation and the maintenance of pulmonary tolerance. Notably, the transfer of tolerogenic DCs in vivo suppresses Th2 allergic responses and protects or even reverses established allergic airway inflammation. Thus, the identification of novel DC subsets that possess immunoregulatory properties and can efficiently control aberrant asthmatic responses is critical for the re-establishment of tolerance and the amelioration of the asthmatic disease phenotype.
变应性哮喘是一种气道慢性炎症性疾病,其特征为气道高反应性(AHR)、慢性气道炎症和针对无害吸入性过敏原的过度辅助性 T 细胞(Th)2 型免疫应答。树突状细胞(DC)是免疫系统中最有效的抗原呈递细胞,充当固有免疫和适应性免疫之间的桥梁。与变应性哮喘相关的是,已知不同的 DC 亚群在启动和维持气道中过敏原驱动的 Th2 免疫应答方面发挥核心作用。然而,重要的研究已经表明,DC 也可以抑制过度的哮喘反应,从而有助于缓解过敏性气道炎症和维持肺耐受。值得注意的是,体内转移致耐受性 DC 可抑制 Th2 变应性反应,并保护甚至逆转已建立的过敏性气道炎症。因此,鉴定具有免疫调节特性并能有效控制异常哮喘反应的新型 DC 亚群,对于重建耐受和改善哮喘疾病表型至关重要。